SHYNDEC Finasteride Tablets or FeiNaXiong’An Pian For Prostatitis
Quantity
Detail
Customer Reviews
Generic name: Finasteride tablets
Chinese Pinyin: FeiNaXiong’An Pian
English name: Finasteride Tablets
Commodity name: Purean
Ingredients: The main ingredient of this product is finasteride.
Properties: This product is a film-coated tablet, white or almost white after removing the coating.
Function and indication: This product is suitable for the treatment of benign prostatic hyperplasia (BPH) with existing symptoms: to improve symptoms. Reduce the risk of acute urinary retention. Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.
Specification: 5mg*10 tablets/box
Usage and dosage: Oral. Recommended dosage: 5 mg each time (1 tablet), once a day, taken on an empty stomach or with food.
Adverse reactions: Finasteride is well tolerated, and the adverse reactions are usually mild and transient.
Taboo: This product is not suitable for women and children. This product is forbidden in the following situations: 1. Those who are allergic to any ingredient of this product; 2. Women who are pregnant and may become pregnant.
Note: Use with caution in patients with liver dysfunction.
Drug interactions: Drug interactions of clinical significance have not been determined. 1. Finasteride has no obvious effect on the cytochrome P450-related drug metabolism enzyme system. The compounds that have been tested in men are propranolol, digoxin, glibenclamide, warfarin, theophylline and antipyrine, none of which have clinically significant interactions with finasteride. 2. Other combination therapy. Although no specific drug interaction studies have been conducted, finasteride and angiotensin-converting enzyme inhibitors, acetaminophen, acetylsalicylic acid, α-blockers, β-blockers, When calcium channel blockers, nitrates for heart disease, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), quinolones and benzodiazepines are used simultaneously, No obvious clinical adverse interactions were found.
Pharmacology and Toxicology: This product is a 4-azasteroid hormone compound, which is a specific type II 5α-reductase competitive inhibitor, inhibits the conversion of peripheral testosterone to dihydrotestosterone, and reduces the dihydrotestosterone in blood, prostate, skin and other tissues Level. The growth and development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves the clinical symptoms of benign prostate hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissue. Toxicology Research Genotoxicity: The results of in vitro bacterial and mammalian cell mutagenicity test and in vitro alkaline elution test showed no mutagenic effects. In the in vitro CHO cell chromosome aberration study, the chromosome aberration rate of CHO cells slightly increased at a concentration of 450-550 μmol of finasteride, which was equivalent to 4000-5000 times the peak plasma concentration after oral administration of 5 mg of this product. In the in vivo chromosome aberration test, the mice were given finasteride 250mg/kg/day (according to AUC, it is equivalent to 228 times the recommended daily dose of 5mg for human clinical use. The calculation method of the dose for all toxicological studies below is the same). The distortion rate did not increase.
Storage: Store at room temperature, shading, and airtight.
Packaging: Aluminum-plastic packaging, 10 pieces/box.
Validity period: 24 months
Approval number: National Medicine Zhunzi H20050550
Company Name: Shanghai Modern Pharmaceutical Co., Ltd.
Chinese Pinyin: FeiNaXiong’An Pian
English name: Finasteride Tablets
Commodity name: Purean
Ingredients: The main ingredient of this product is finasteride.
Properties: This product is a film-coated tablet, white or almost white after removing the coating.
Function and indication: This product is suitable for the treatment of benign prostatic hyperplasia (BPH) with existing symptoms: to improve symptoms. Reduce the risk of acute urinary retention. Reduce the risk of transurethral resection of the prostate (TURP) and prostatectomy.
Specification: 5mg*10 tablets/box
Usage and dosage: Oral. Recommended dosage: 5 mg each time (1 tablet), once a day, taken on an empty stomach or with food.
Adverse reactions: Finasteride is well tolerated, and the adverse reactions are usually mild and transient.
Taboo: This product is not suitable for women and children. This product is forbidden in the following situations: 1. Those who are allergic to any ingredient of this product; 2. Women who are pregnant and may become pregnant.
Note: Use with caution in patients with liver dysfunction.
Drug interactions: Drug interactions of clinical significance have not been determined. 1. Finasteride has no obvious effect on the cytochrome P450-related drug metabolism enzyme system. The compounds that have been tested in men are propranolol, digoxin, glibenclamide, warfarin, theophylline and antipyrine, none of which have clinically significant interactions with finasteride. 2. Other combination therapy. Although no specific drug interaction studies have been conducted, finasteride and angiotensin-converting enzyme inhibitors, acetaminophen, acetylsalicylic acid, α-blockers, β-blockers, When calcium channel blockers, nitrates for heart disease, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), quinolones and benzodiazepines are used simultaneously, No obvious clinical adverse interactions were found.
Pharmacology and Toxicology: This product is a 4-azasteroid hormone compound, which is a specific type II 5α-reductase competitive inhibitor, inhibits the conversion of peripheral testosterone to dihydrotestosterone, and reduces the dihydrotestosterone in blood, prostate, skin and other tissues Level. The growth and development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves the clinical symptoms of benign prostate hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissue. Toxicology Research Genotoxicity: The results of in vitro bacterial and mammalian cell mutagenicity test and in vitro alkaline elution test showed no mutagenic effects. In the in vitro CHO cell chromosome aberration study, the chromosome aberration rate of CHO cells slightly increased at a concentration of 450-550 μmol of finasteride, which was equivalent to 4000-5000 times the peak plasma concentration after oral administration of 5 mg of this product. In the in vivo chromosome aberration test, the mice were given finasteride 250mg/kg/day (according to AUC, it is equivalent to 228 times the recommended daily dose of 5mg for human clinical use. The calculation method of the dose for all toxicological studies below is the same). The distortion rate did not increase.
Storage: Store at room temperature, shading, and airtight.
Packaging: Aluminum-plastic packaging, 10 pieces/box.
Validity period: 24 months
Approval number: National Medicine Zhunzi H20050550
Company Name: Shanghai Modern Pharmaceutical Co., Ltd.